Clinical Trials Sponsored by TAK-Circulator Co.

Total 333 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults

Hospital-acquired Pneumonia

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia

Community Acquired Pneumonia

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Hemophilia A

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Study of TQH2929 in Healthy Adult Subjects

Psoriasis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

Sinusitis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

Hematological Tumors

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Terminated

Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma

Advanced High-grade Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.

Diabetes Mellitus, Type 2

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors

Advanced Tumors

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumor

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Terminated

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Pancreatic Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers

Psoriasis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial Evaluating the Safety of the TQB2103 for Injection

Advanced Malignant Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

Atopic Dermatitis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers

Advanced Cancers

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers

Advanced Cancer

China
Organon and Co
PT. Schering-Plough. Tbk Indonesia

Completed

Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)

Hypercholesterolemia | Coronary Arteriosclerosis
Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Cervical Cancer | Ovarian Cancer

China
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer (N-PRC)

Rectal Cancer | Locally Advanced
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC (ALTER-L013)

NSCLC

China
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) (ALTER-G-001)

Gastrointestinal Tumors

China
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study) (Neptune)

Chronic Hepatitis b
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Sichuan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Anlotinib

China
Zhejiang University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients (ALTER-C-002)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Colonic Diseases | Intestinal Diseases | Colorectal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Colorectal Cancer | RAS and BRAF Wild-type

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Fudan University

Unknown

A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics

Solid Tumor

China
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Beijing Biostar Pharmaceuticals...

Recruiting

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Esophageal Cancer

China
Shanghai Zhongshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors (FAITH)

Hepatocellular Carcinoma

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

Esophageal Neoplasms

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nanjing Medical University

Completed

A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (ALTN)

Advanced Cancer

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Non-squamous Cell Non-Small Cell Lung Cancer

China
Zhejiang Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Innovent Biologics (Suzhou)...

Unknown

The Efficacy and Safety of Antinib Hydrochloride Combined With Sindilumab in Advanced NSCLC Patients

NSCLC

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (ALTER-HN005)

Nasopharyngeal Neoplasms
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
National University Hospital, Singapore
Eisai Co., Ltd.; Tan Tock Seng Hospital

Unknown

Phase II Study of Single Agent Lenvatinib

Breast Cancer

Singapore
Henan Provincial People's Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC (ALTER-L025)

Non-squamous Cell Non-Small Cell Lung Cancer

China
Jiangxi Provincial Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients (ALTER-E005)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Carcinoma, Squamous Cell | Esophageal Neoplasms | Esophageal Diseases | Neoplasms, Squamous Cell | Esophageal Squamous Cell Carcinoma

China
Gadjah Mada University
Morinaga Milk Industry Co., LTD; PT Kalbe Farma Tbk

Active, not recruiting

Ingestion Effect of Formula Milk With Triple Bifidobacteria Strains on Fecal Quality and Metabolites in Healthy Children

Children, Only

Indonesia
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Qilu Hospital of Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer (ACDFNSNSCLC)

Non Small Cell Lung Cancer
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Non Small Cell Lung Cancer

China
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib or Penpulimab in Combination With RAI for DTC

Thyroid Cancer

China
First People's Hospital of Hangzhou
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

Recurrent High-grade Glioma

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China

Clinical Trials Sponsored by TAK-Circulator Co.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations